2-[2-Nitro-4-(trifluoromethyl)phenyl]ethanamine | 771579-57-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[2-Nitro-4-(trifluoromethyl)phenyl]ethanamine
• CAS: 771579-57-8
• 化学式: C₉H₉F₃N₂O₂
• 分子量: 234.178
• InChiKey: ODWDTPCDWBNLRC-UHFFFAOYSA-N

物化性质

• 沸点：
  270.9±35.0 °C(Predicted)
• 密度：
  1.367±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-[2-Nitro-4-(trifluoromethyl)phenyl]ethanamine 、 甲基磺酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 以74%的产率得到N-[2-[2-nitro-4-(trifluoromethyl)phenyl]ethyl]methanesulfonamide
  参考文献：
  名称：

  [EN] SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS
  [FR] DERIVES DE BISARYLUREE

  摘要：

  公开号：

  WO2005075425A3
• 作为产物：
  描述：

  2-硝基-4-(三氟甲基)苯乙腈 在 硼烷四氢呋喃络合物 、 盐酸 、 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 73.0h， 以77%的产率得到2-[2-Nitro-4-(trifluoromethyl)phenyl]ethanamine
  参考文献：
  名称：

  [EN] SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS
  [FR] DERIVES DE BISARYLUREE

  摘要：

  公开号：

  WO2005075425A3

文献信息

• Non-systemic TGR5 agonists
  申请人：Venenum Biodesign, LLC

  公开号：US10654834B2

  公开（公告）日：2020-05-19

  The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

  本发明涉及式（I）和式（II）的三环化合物或其药学上可接受的盐。本发明的三环化合物是有用的非系统性 TGR5 激动剂，可用于治疗人类糖尿病疾病。本发明提供了一种含有式（I）和式（II）三环化合物的药物组合物及其制造方法，以及一种通过给药治疗代谢紊乱患者的方法。本发明的化合物可与其他抗糖尿病药物联合使用。
• Bisarylurea derivatives
  申请人：Buchstaller Hans-Peter

  公开号：US20070161677A1

  公开（公告）日：2007-07-12

  The present invention relates to bisarylurea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
• NOVEL NON-SYSTEMIC TGR5 AGONISTS
  申请人：Venenum Biodesign, LLC

  公开号：US20190330191A1

  公开（公告）日：2019-10-31

  The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
• [EN] SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES DE BISARYLUREE
  申请人：MERCK PATENT GMBH

  公开号：WO2005075425A3

  公开（公告）日：2006-12-14